Product Pathways - CD Markers
CD82 Antibody #8854
|8854S||100 µl (10 western blots)||---||In Stock||---|
|8854||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting
Specificity / Sensitivity
CD82 recognizes endogenous levels of total CD82 protein.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Asn204 of human CD82 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Western blot analysis of extracts from 293T cells, mock transfected (-) or transfected with a tagged human CD82 construct (hCD82; +), using CD82 Antibody.
CD82 (KAI1) belongs to the tetraspanin family, which is characterized by four transmembrane domains, one short extracellular domain (ECL1), and one long extracellular domain (ECL2). CD82 does not have enzymatic activity and appears to function by regulating the trafficking of other proteins and organization of the cell membrane (1). CD82 was originally described as a costimulator for T cells that directly associates with CD4 and CD8, and was subsequently identified during a screen as a metastasis suppressor in prostate cancer (2,3). CD82 has since been found to act as a metastasis suppressor in a variety of cancers, and its downregulation is associated with poor prognosis in research studies (4-6). CD82 suppresses metastasis through multiple mechanisms including inhibition of cell motility and invasion by modulating c-Met and the urokinase plasminogen activator surface receptor (uPAR), as well as promotion of homotypic cell-cell adhesion by stabilizing interactions between E-cadherin and β-catenin (7-9).
- Tsai, Y.C. and Weissman, A.M. (2011) FEBS Lett 585, 3166-73.
- Imai, T. et al. (1992) J Immunol 149, 2879-86.
- Dong, J.T. et al. (1995) Science 268, 884-6.
- Liu, F.S. et al. (2003) Clin Cancer Res 9, 1393-8.
- Yang, X. et al. (2001) Cancer Res 61, 5284-8.
- Lombardi, D.P. et al. (1999) Cancer Res 59, 5724-31.
- Sridhar, S.C. and Miranti, C.K. (2006) Oncogene 25, 2367-78.
- Bass, R. et al. (2005) J Biol Chem 280, 14811-8.
- Abe, M. et al. (2008) Cancer Lett 266, 163-70.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.